Engineered Context-Sensitive Agonism: Tissue-Selective Drug Signaling through a G Protein-Coupled Receptor

J Pharmacol Exp Ther. 2017 Feb;360(2):289-299. doi: 10.1124/jpet.116.237149. Epub 2016 Nov 15.

Abstract

Drug discovery strives for selective ligands to achieve targeted modulation of tissue function. Here we introduce engineered context-sensitive agonism as a postreceptor mechanism for tissue-selective drug action through a G protein-coupled receptor. Acetylcholine M2-receptor activation is known to mediate, among other actions, potentially dangerous slowing of the heart rate. This unwanted side effect is one of the main reasons that limit clinical application of muscarinic agonists. Herein we show that dualsteric (orthosteric/allosteric) agonists induce less cardiac depression ex vivo and in vivo than conventional full agonists. Exploration of the underlying mechanism in living cells employing cellular dynamic mass redistribution identified context-sensitive agonism of these dualsteric agonists. They translate elevation of intracellular cAMP into a switch from full to partial agonism. Designed context-sensitive agonism opens an avenue toward postreceptor pharmacologic selectivity, which even works in target tissues operated by the same subtype of pharmacologic receptor.

MeSH terms

  • Allosteric Regulation / drug effects
  • Animals
  • CHO Cells
  • Cricetinae
  • Cricetulus
  • Cyclic AMP / metabolism
  • Drug Discovery*
  • Female
  • Heart / drug effects
  • Intracellular Space / drug effects
  • Intracellular Space / metabolism
  • Male
  • Mice
  • Muscarinic Agonists / adverse effects
  • Muscarinic Agonists / pharmacology*
  • Receptor, Muscarinic M2 / agonists*
  • Receptor, Muscarinic M2 / metabolism*
  • Signal Transduction / drug effects

Substances

  • Muscarinic Agonists
  • Receptor, Muscarinic M2
  • Cyclic AMP